Abstract:Deguelin, a rotenoid of the flavonoid family, has been reported to possess antiproliferative and anticarcinogenic activities in several cell lines and tumor models. However, it is still unclear whether deguelin effectively inhibits tumor‐associated lymphangiogenesis and lymphatic metastasis. Since tumor production of vascular endothelial cell growth factor (VEGF)‐D was associated with tumor lymphangiogenesis and lymphatic metastasis, we established the mouse lymphatic metastasis model by transfecting high expression VEGF‐D into LL/2 Lewis lung cells (VEGF‐D‐LL/2) and explored the effects of deguelin on lymphatic metastasis in the immunocompetent C57BL/6 mice. Our results indicated that deguelin inhibited proliferation, migration of VEGF‐D‐LL/2 cells via downregulating AKT and mitogen‐activated protein kinase pathway and interfered tube formation of lymphatic vascular endothelial cells on matrigel at nanomolar concentrations. Deguelin significantly downregulated the expression of VEGF‐D both at mRNA and protein levels in VEGF‐D‐LL/2 cells in a dose‐dependent manner. In the in vivo study, intraperitoneal administration of deguelin (4 mg/kg) remarkably inhibited the tumor‐associated lymphangiogenesis and lymphatic metastasis. The rates of lymph node and lung metastasis in deguelin‐treated mice were 0 and 16.7% compared with 58.3 and 83.3% in control group mice, respectively. Deguelin also resulted in a remarkable delay of tumor growth and prolongation of life span. Immunohistochemical staining with antibodies against VEGF‐D, LYVE‐1 and VEGFR‐3 revealed fewer positive vessel‐like structures in deguelin‐treated mice compared with control group mice. Taken together, we demonstrate for the first time that deguelin suppresses tumor‐associated lymphangiogenesis and lymphatic metastasis by downregulation of VEGF‐D both in vitro and in vivo.

Deguelin Induces The Apoptosis Of Lung Squamous Cell Carcinoma Cells Through Regulating The Expression Of Galectin-1

Deguelin Attenuates Non-Small-Cell Lung Cancer Cell Metastasis by Upregulating PTEN/KLF4/EMT Signaling Pathway.

Deguelin Induces Apoptosis in Colorectal Cancer Cells by Activating the P38 MAPK Pathway.

Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis.

Deguelin Attenuates Non-Small Cell Lung Cancer Cell Metastasis Through Inhibiting the CtsZ/FAK Signaling Pathway

Antitumor Effects of Deguelin on H460 Human Lung Cancer Cells in Vitro and in Vivo: Roles of Apoptotic Cell Death and H460 Tumor Xenografts Model.

Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3/FBW7-mediated Mcl-1 destabilization

Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization

Deguelin induces PUMA-mediated apoptosis and promotes sensitivity of lung cancer cells (LCCs) to doxorubicin (Dox)

Repression of Noxa by Bmi1 Contributes to Deguelin-Induced Apoptosis in Non-Small Cell Lung Cancer Cells

Deguelin Impairs Cell Adhesion, Migration And Invasion Of Human Lung Cancer Cells Through The Nf-Kappa B Signaling Pathways

Deguelin Impairs Cell Adhesion, Migration and Invasion of Human Lung Cancer Cells through the NF-[Formula: see text]B Signaling Pathways.

Study of Proliferation Inhibition and Apoptosis Induction of Deguelin in Human Hepatocellular Cancer Cell Line SMMC-7721

Deguelin Exerts Anticancer Activity of Human Gastric Cancer MGC-803 and MKN-45 Cells in Vitro

Effects of deguelin on proliferation and apoptosis of gastric cancer cells MKN-45

Honokiol induces apoptosis of lung squamous cell carcinoma by targeting FGF2-FGFR1 autocrine loop.

Deguelin—An Inhibitor to Tumor Lymphangiogenesis and Lymphatic Metastasis by Downregulation of Vascular Endothelial Cell Growth Factor‐d in Lung Tumor Model

Deguelin inhibits epithelial-to-mesenchymal transition and metastasis of human non-small cell lung cancer cells by regulating NIMA-related kinase 2

Deguelin Enhances the Sensitivity of Human Gastric Carcinoma Cells SGC-7901 to 5-Fluorouracil

Induction of DNA damage by deguelin is mediated through reducing DNA repair genes in human non-small cell lung cancer NCI-H460 cells.

Deguelin inhibits the glioblastoma progression through suppressing CCL2/NFκB signaling pathway